EstroG-100^® significantly alleviated menopausal symptoms and improved vaginal dryness following 12 weeks of supplementation in a randomized, double-blind, placebo-controlled trial involving a multiethnic population of pre-, peri-, and postmenopausal women in the United States. Compared with placebo, EstroG-100^® demonstrated greater improvement in 10 KMI items menopausal symptoms, with significant benefits across multiple vasomotor, psychological, and physical symptoms. Importantly, these clinical benefits were achieved without significant changes in body weight, BMI, serum estradiol, or FSH levels, and no adverse events were reported. These findings support EstroG-100^® as a safe and effective non-hormonal intervention for the management of menopausal symptoms across diverse populations.